美银发表研究报告指，海吉亚医疗(06078.HK) 去年总收入按年跌9.1%至44亿元人民币，低于预期，应占净利润为5.983亿元人民币，按年跌12.4%，非国际财务报告准则调整后净利润为6.023亿元人民币，按年跌15.6%。
该行表示，将集团今年、明年及2027年收入预测分别下调18%、18%及19%，各年经调整每股盈利预测分别下调22%、23%及22%，其目标价由17.9元下调至16.5元，重申评级为“买入”，由于中国肿瘤市场规模庞大。该行相信患者数量和手术病例数将继续迅速地增长。同时，该公司还有两家新医院正在兴建中，并将于2025年开始营运。新医院和新计划的启动可以提供清晰的公司增长前景。(ca/k)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.